Evolution of treatments for patients with acute lung injury

Expert Opinion on Investigational Drugs

Volumn 14, Issue 5, 2005, Pages 633-645

  Esper, Annette M ^a   Martin, Greg S ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acute lung injury; Acute respiratory distress syndrome; Anti inflammatory mediators; Anticoagulants; Clinical trials; Drug therapy; Surfactant

Indexed keywords

2 OXO 4 THIAZOLIDINECARBOXYLIC ACID; ACETYLCYSTEINE; ACTIVATED PROTEIN C; ANTICOAGULANT AGENT; ANTIOXIDANT; ANTITHROMBIN; ATRIAL NATRIURETIC FACTOR; ATRIAL NATRIURETIC FACTOR ALPHA; BERACTANT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; COMPLEMENT RECEPTOR; CORTICOSTEROID; CYTOKINE RECEPTOR ANTAGONIST; DIPALMITOYLPHOSPHATIDYLCHOLINE; DROTRECOGIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GROWTH FACTOR; IBUPROFEN; INTERLEUKIN 10; LEUKOCYTE ELASTASE INHIBITOR; LISOFYLLINE; LUCINACTANT; METHYLPREDNISOLONE; NITRIC OXIDE; PROSTACYCLIN; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE INHIBITOR; SIVELESTAT; SURFACTANT; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST;

ACUTE LUNG INJURY; ADULT RESPIRATORY DISTRESS SYNDROME; ARTIFICIAL VENTILATION; CELL PROTECTION; CLINICAL TRIAL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MECHANISM; HUMAN; HYDROSTATIC PRESSURE; HYPOXEMIA; INTENSIVE CARE; LUNG COMPLIANCE; LUNG EDEMA; LUNG HEMODYNAMICS; MORTALITY; NONHUMAN; NUTRITION; ONCOTIC PRESSURE; OXYGENATION; PATHOGENESIS; PROGNOSIS; PROPHYLAXIS; RESPIRATORY FAILURE; REVIEW; RISK FACTOR; SEPSIS; SURVIVAL; TREATMENT FAILURE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTICOAGULANTS; CLINICAL TRIALS; DRUGS, INVESTIGATIONAL; HUMANS; RESPIRATORY DISTRESS SYNDROME, ADULT; SURFACE-ACTIVE AGENTS;

EID: 20344404189     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.14.5.633     Document Type: Review

References (99)

1. FRUTOS-VIVAR F, NIN N, ESTEBAN A: Epidemiology of acute lung injury and acute respiratory distress syndrome. Curr. Opin. Crit. Care (2004) 10(1):1-6.
2. MILBERG JA, DAVIS DR, STEINBERG KP, HUDSON LD: Improved survival of patients with acute respiratory distress syndrome (ARDS). JAMA (1995) 273:306-309.
3. MARTIN GS, BERNARD GR: Airway and lung dysfunction in sepsis. Intensive Care Med. (2001) 27(Suppl.):S63-S79.
4. THE ARDS CLINICAL TRIALS NETWORK: Ventilation with lower tidal volume as compared with traditional tidal volume for acute lung injury and acute respiratory distress syndrome. N. Engl. J. Med. (2000) 342:1301-1308.
5. WARE LB, MATTHAY MA: The acute respiratory distress syndrome. N. Engl. J. Med. (2000) 342(18): 1334-1349.
6. THE ARDS CLINICAL TRIALS NETWORK: Randomized, placebo-controlled trial of lisofylline for early treatment of acute lung injury and acute respiratory distress syndrome. Crit. Care Med. (2002) 30(1):1-6.
7. BERNARD GR, WHEELER AP, NAUM CC et al.: A placebo-controlled randomized trial of IL-10 in acute lung injury. Chest (1999) 116(4):260S (Abstract).
8. KIDOI Y, HINOHANA H, KUNIMOTO R et al.: Pilot study of the effects of ONO-5046 in patients with acute respiratory distress syndrome. Anesth. Analg. (2004) 99:872-877.
9. LEE WL AND DOWNEY GP. Leukocyte elastase: physiological functions and role in acute lung injury. Am. J. Respir. Crit. Care Med. (2001)164:896-904.
10. ZEIHER BL, ARTIGAS A, VINCENT JL et al.:Neutrophil elastase inhibition in acute lung injury: results of the Strive study. Crit. Care Med. (2004) 32(8):1695-702.
11. KADOI Y, HINOHARA H, KUNIMOTO F et al.: Pilot study of the effects of ONO-5046 in patients with acute respiratory distress syndrome. Anesth. Anal. (2004) 99:872-7.
12. DELACOURT C, HERIGAULT S, DELCLAUX C et al.: Protection against acute lung injury by intravenous or intratracheal pretreatment with EPI-HNE-4, a new potent neutrophil elastase inhibitor. Am. J. Respir. Cell Mol. Biol. (2002) 26:290-297.
13. HONORE S, ATTALAH, HL, AZOULAY E et al.: Beneficial effect of an inhibitor of leukocyte elastase (EPI-HNE-4) in presence of repeated lung injuries. Shock (2004) 22(2):131-136.
14. NAKAMU T, OGAMI Y: Prophylactic effects of recombinant human superoxide dismutase in neonatal lung injury induced by the intratracheal instillation of endotoxin in piglets. Biuol. Neonate (2001) 80(2):163-168.
15. BERNARD G, WHEELER A, ARONS M et al.: A trial of antioxidants N-acetylcysteine and procysteine in ARDS. Chest (1997) 112:164-172.
16. SCHUSTER DP, METZLER M, OPA S et al.: Recombinant platelet-activating factor acetylhydrolase to prevent acute respiratory distress syndrome and mortality in severe sepsis: Phase IIb, multicenter, randomized, placebo-controlled, clinical trial. Crit Care Med. (2003) 31(6):1612-1619.
17. OPAL S, LATERRE PF, ABRAHAN E et al.: Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: results of a Phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial. Crit. Care Med. (2004) 32(2):332-341.
18. GUNTHER A, WALMRATH D, GRIMMINGER F, WERNER A: Pathophysiology of acute lung injury. In: Seminars in Respiratory and Crit. Care Med. Hall JB and Schmidt GA (Eds.), Thieme Medical Publishers (2001) 22(3):247-258.
19. ZIMMERMAN JL, DELLINGER RP, STRAUBE RC, LEVIN JL: Phase I trial of the recombinant soluble complement receptor 1 in acute lung injury and acute respiratory distress syndrome. Crit. Care Med. (2000) 28(9):3149-3154.
20. RIOUX P: TP-10 (AVANT Immunotherapeutics). Curr. Opin. Investig. Drugs. (2001) 2(3):364-371.
21. SPRUNG CL, CARALIS PV, MARCIAL EH et al.: The effects of high-dose corticosteroids in patients with septic shock. N. Engl. J. Med. (1984) 311(18):1137-1143.
22. BERNARD GR, LUCE JM, SPRUNG CL et al.: High-dose corticosteroids in patients with the adult respiratory distress syndrome. N. Engl. J. Med. (1987) 317:1565-1570.
23. MEDURI GU, HEADLEY AS, GOLDEN E: Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome. JAMA (1998) 280:159-165.
24. ABRAHAM E, PARK YC, CONINGTON P et al.: Liposomal prostaglandin E1 in acute respiratory distress syndrome: a placebo-controlled, randomized, double-blind, multicenter clinical trial. Crit. Care Med. (1996) 24(1):10-15.
25. ABRAHAM E, BAUGHMAN T, FLETCHER E et al.: Liposomal prostaglandin E1 (TLC C-53) in acute respiratory distress syndrome: a controlled, randomized, double-blind, multicenter clinical trial. TLC C-53 ARDS Study Group. Crit. Care Med. (1999) 27(8):1478-1485.
26. VINCENT JL, BRASE R, SANTMAN F et al.: A multicentre, double-blind, placebo-controlled study of liposomal prostaglandin E1 (TLC C-53) in patients with acute respiratory distress syndrome. Intensive Care Med. (2001) 27(10):1578-1583.
27. WALMRATH D, SCHNEIDER T, PILCH J, GRIMMINGER F, SEEGER W: Aerosolized prostacyclin in adult respiratory distress syndrome. Lancet (1993) 342(8877):961-962.
28. VAN HEERDEN PV, BARDEN A, MICHALOPOULOS N, BULSARA MK, ROBERTS BL: Dose-response to inhaled aerosolized prostacyclin for hypoxemia due to ARDS. Chest (2000) 117(3):819-827.
29. 2) in acute respiratory distress syndrome: Impact of primary (pulmonary injury) and secondary (extrapulmonary injury) disease on gas exchange response. Crit. Care Med. (2001) 29(1):57-62.
30. GATTINONI L, PELOSI P, VITALE G et al.: Body position changes redistribute lung computed topographic density in patients with acute respiratory failure. Aneaesthesiology (1991) 74:15-23.
31. BERNARD GR, VINCENT JL, LATERRE PF et al.: Efficacy and safety of recombinant human activated protein C for severe sepsis. N. Engl. J. Med. (2001)344:699-709.
32. DHAINAUT JF, LATERRE PF, JANES JM et al.: Drotecogin alfa (activated) in the treatment of severe sepsis patients with multi-organ dysfunction: data from the PROWESS trial. Intensive Care Med. (2003)29(6):894-903.
33. VINCENT JL, ANGUS DC, ARTIGAS A et al.: Effects of drotecogin alfa (activated) on organ dysfunction in the PROWESS trial. Crit. Care Med. (2003) 31(3):834-40.
34. WARREN BL, EID A, SINGER P et al.: Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA (2001) 286(15):1869-78.
35. CARRAWAY MS, WELTY-WOLF KE, MILLER DL et al.: Blockade of tissue factor: treatment for organ injury in established sepsis. Am. J. Respir. Crit. Care Med. (2003) 167(9):1200-9.
36. ABRAHAM E, REINHART K, OPAL S et al.: Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA (2003) 290(2)238-47.
37. IQBAL O, MAHMUT T, HOPPENSTEADT D et al.: Antithrombotic agents in the management of sepsis. Turk. J. Haem. (2002) 19(3):349-389.
38. LEWIS JF, JOBE AH: Surfactant and the adult respiratory distress syndrome. Am. Respir. Dis. (1993) 147:218-233.
39. HOLM BA, MATALON S: Role of pulmonary surfactant in the development and treatment of adult respiratory distress syndrome. Anesth. Analg. (1989) 69:805-818.
40. PISON U, OBERTAKE U, BRAND M et al.: Altered pulmonary surfactant in uncomplicated and septicemia-complicated courses of acute respiratory failure. J. Trauma (1990) 30:19-26.
41. GREGORY TJ, LONGMORE WJ, MOXLEY MA et al.: Surfactant chemical composition and biophysical activity in acute respiratory distress syndrome. J. Clin Invest. (1991) 99:1976-1981.
42. HAITSMA JJ, PAPADAKOS PJ, LACHMANN B: Surfactant therapy for acute lung injury/acute respiratory distress syndrome. Curr. Opin. Crit. Care (2004) 10:18-22.
43. EISNER MD, PARSONS P, MATTHAY MA, WARE L,GREENE K: Plasma surfactant protein levels and clinical outcomes in patients with acute lung injury. Thorax (2003) 58(11):983-988.
44. SPRAGG RG, LEWIS JF, WURST W et al.: Treatment of acute respiratory distress syndrome with recombinant surfactant protein C surfactant. Am. J. Respir. Crit. Care Med. (2003) 167(11):1562-6.
45. LEWIS JF: Surfactant - Where are we in 2003? Can. Resp J. (2003) 11(3):204-206.
46. KESECIOGLU JM, SCHULTZ MJ, LUNDBERG D, LAUVEN PM, LACHMANN B: Treatment of ALI/ARDS with surfactant. Am. J. Respir. Crit. Care Med. (2001) 163(5):A819 (Asbtract).
47. ANZUETO A, BAUGHMAN RP, GUNTUPALLI KK et al.: Aerosolized surfactant in adults with sepsis-induced acute respiratory distress syndrome. N. Engl. J. Med. (1996) 334:1417-1422.
48. WISWELL TE, SMITH RM, KATZ LB et al.: Bronchopulmonary segmental lavage with Surfaxin (KL (4)-surfactant) for acute respiratory distress syndrome. Am. J. Respir. Ciit. Care Med. (1999) 160(4):1188-1195.
49. SPRAGG RG, LEWIS JF, WALMRATH HD et al.: Effect of recombinant surfactant protein C-based surfactant on the acute respiratory distress syndrome. N. Engl. J. Med. (2004) 351:884-892.
50. BHATIA M AND MOOCHHALA S: Role of inflammatory mediators in the pathophysiology of acute respiratory distress syndrome. J. Path. (2004) 202:145-156.
51. VOERMAN HJ, VAN SCHIJNDEL RJ, GROENEVELD AB et al.: Effects of recombinant human growth hormone in patients with severe sepsis. Ann. Surg. (1992) 216(6):648-55.
52. TAKALA J, RUOKONEN E, WEBSTER NR et al.: Increased mortality associated with growth hormone treatment in critically ill adults. N. Engl. J. Med. (1999) 341(11):785-792.
53. LIU Z, YU Y, JIANG Y, LI J: Growth hormone increases circulating neutrophil activation and provokes lung microvascular injury in septic peritonitis rats. J. Surg. Res. (2002) 105(2):195-199.
54. AZOULAY E, ATTALAH H, YANG K et al.: Exacerbation by granulocyte colony-stimulating factor of prior acute lung injury: implication of neutrophils. Crit. Care Med. (2002) 30(9):2115-2122.
55. ATTALAH HL, AZOULAY E, YANG K et al.: Granulocyte colony-stimulating factor enhances host defenses against bacterial pneumonia following peritonitis in nonneutropenic rats. Crit. Care Med. (2002) 30(9):2107-14.
56. AZOULAY E, ATTALAH H, HERIGAULT S et al.: Exacerbation with granulocyte colony-stimulating factor of prior acute lung injury during neutropenia recovery in rats. Crit. Care Med. (2003) 31((1):L157-L165.
57. ROOT RK, LODATO RF, PATRICK W et al.: Multicenter, double-blind, placebo-controlled study of the use of filgastrim in patients hospitalized with pneumonia and severe sepsis. Crit. Care Med. (2003) 31:367-373.
58. WUNDERINK RG, LEEPER KV, SCHEIN R et al.: Filgastrim in patients with pneumonia and severe sepsis or septic shock. Chest (2001) 119:523-529.
59. TANAKA H, NISHINO M, NAKAMORI Y et al.: Granulocyte colony-stimulating factor stiffens leukocytes but attenuates inflammatory response without lung injury in septic patients. J. Trauma (2001) 51:1110-1116.
60. PRESNEILL JJ, HARRIS T, STEWART AG, CADE JF, WILSON JW: A randomized Phase II trial of granulocyte-macrophage colony-stimulating factor therapy in severe sepsis with respiratory dysfunction. Am. J. Respir. Crit. Care Med. (2002) 166:138-143.
61. MATUTE-BELLO G, LILES WC, RADELLA F et al.: Modulation of neutrophil apoptosis by granulocyte colony-stimulating factor and granulocyte/macrophage colony-stimulating factor during the course of acute respiratory distress syndrome. Crit. Care Med. (2000) 28(1):1-7.
62. PELAEZ A, BECHARA RI, JOSHI PC, BROWN LAS, GUIDOT DM: Granulocyte/macrophage colony-stimulating factor treatment improves alveolar epithelial barrier function in alcoholic rat lung. Am. J. Physiol. Lung Cell Mol. Physiol. (2004) 286(1):L106-L111.
63. PAINE R, WILCOXEN SE, MORRIS SB et al.: Transgenic overexpression of granulocyte macrophage-colony stimulating factor in the lung prevents hyperoxic lung injury. Am. J. Pathol. (2003) 163(6):2397-406.
64. SUGAHARA K, RUBI JS, MASON RJ et al.: Keratinocyte growth factor increases mRNAs for SP-A and SP-B in adult rat alveolar type II cells in culture. Am. J. Physiol. (1995) 269:L355-L350.
65. GUO J, YI ES, HAVILL AM et al.: Intravenous keratinocyte growth factor protects against experimental pulmonary injury. Am. J. Physiol. (Lung Cell Mol. Physiol.) (1998) 259:L800-L805.
66. STERN JB, FIEROBE L, PAUGAM C et al.: Keratinocyte growth factor and hepatocyte growth factor in bronchoalveolar lavage fluid in acute respiratory distress syndrome patients. Crit. Care Med. (2000) 28:2326-2333.
67. HART CM: Nitric oxide in adult lung disease. Chest (1999) 115(5):1407-1417.
68. DELLINGER RP, ZIMMERMAN JL, TAYLOR RW et al.: Effects of inhaled nitric oxide in patients with acute respiratory distress syndrome: results of a randomized Phase II trial. Crit. Care Med. (1998) 26:15-23.
69. LUNDIN S, MANG H, SMITHIES M, STENQVIST O, FROSTELL C: Inhalation of nitric oxide in acute lung injury: results of European multicentre study. Intensive Care Med. (1999) 25:911-919.
70. TAYLOR, RW, ZIMMERMAN JL, DELLINGER, RP et al.: Low-dose inhaled nitric oxide in patients with acute lung injury: a randomized controlled trial. JAMA (2004) 291:1603-1609.
71. TAANBE E, UEDA M, ENDO M, KIAJIMA M: Effect of acute lung injury and coexisting disorders on plasma concentrations of atrial natriuretic peptide. Crit. Care Med. (1994) 22(11):1762-1768.
72. TANABE E, UEDA M, ENDO M, KITAJIMA M: The effect of atrial natriuretic peptide on pulmonary acid injury in a pig model. Am. J. Respir. Crit. Care Med. (1996) 154(5):1351-1356.
73. MITAKA C, HIRATA Y, NAGURA T, TSUNODA Y, AMAHA K: Beneficial effect of atrial natriuretic peptide on pulmonary gas exchange in patients with acute lung injury. Chest (1998) 114:223-228.
74. LEWIS CA, MARTIN GS: Understanding and managing fluid balance in patients with acute lung injury. Curr. Opin. Crit. Care (2004) 10(1):13-17.
75. MITCHELL JP, SCHULLER D, CALANDRINO FS, SCHUSTER DP: Improved outcome based on fluid management in critically ill patients requiring pulmonary artery catheterization. Am. Rev. Respir. Dis. (1992) 145:990-998.
76. MARTIN GS, MANGIALARDI RJ, WHEELER AP et al.: Albumin and furosemide therapy in hypoproteinemic patients with acute lung injury. Crit. Care Med. (2002) 30(10):2175-2182.
77. MARTIN GS, MOSS M, WHEELER AP, BERNARD GR: The addition of albumin to furosemide therapy improves oxygenation in hypoproteinemic ALI. Am. J. Respir. Crit. Care Med. (2004) 169(7):A256.
78. QUINLAN GJ, MUMBY S, MARTIN GS et al.: Albumin influences total plasma antioxidant capacity favorably in patients with acute lung injury. Crit. Care Med. (2004) 32(3):755-759.
79. CALDERWOOD HW, MODELL JH, RUIZ BC, BROGDON JE, HOOD CI: Pulmonary lavage with liquid fluorocarbon in a model of pulmonary edema. Anesthesiology (1973) 38:141-144.
80. MODELL JH, NEWBY EJ, RUIZ BC: Long-term survival of dogs after breathing oxygenated fluorocarbon liquid. Fed. Proc. (1979) 29:1731-1736.
81. TUTUNCU AS, FAITHFUL NS, AKPIR K, LACHMANN B: Improvement of gas exchange dose dependently by intratracheal perfluorocarbon administration in adult animals with acute respiratory failure. Clin. Intensive Care (1992) 3(Suppl.):72.
82. RICHMANN PS, WOLFSON MR, SHAFFER TH: Lung lavage with oxygenated perfluorochemical liquid in acute lung injury. Crit. Care Med. (1993) 20:768-774.
83. NESTI FD, FUHRMAN BP, STEINHORN DM et al.: Perfluorocarbon-associated gas exchange in gastric aspiration. Crit. Care Med. (1994) 22(9):1445-1452.
84. HIRSCHL RB, TOOLEY R, PARENT A, JOHNSON K, BARTLET RH: Evaluation of gas exchange, pulmonary compliance, and lung injury during total and partial liquid ventilation in the acute respiratory distress syndrome. Crit. Care Med. (1996) 24(6):1001-1008.
85. LOWE C, SHAFFER T: Pulmonary vascular resistance in the fluorocarbon-filled lung. J. Appl. Physiol. (1986) 60:154-159.
86. LANGE NR, KOZLOWSKI JK, GUST R, SHAPIRO SD, SCHUSTER DP: Effect of partial liquid ventilation on pulmonary vascular permeability and edema after experimental acute lung injury. Am. J. Respir. Crit. Care Med. (2000) 162(1)271-277.
87. HIRSCHL RB, PRANIKOFF T. WISE C: Initial experience with partial liquid ventilation in adult patients with the acute respiratory distress syndrome. JAMA (1996) 275:383-389.
88. HIRSCHL RB, CONRAD S, KAISER R et al.: Partial liquid ventilation in adult patients with ARDS: a multicenter Phase I-II trial. Ann. Surg. (1998) 228(5):692-700.
89. HIRSCHL RB, CROCE M, GORE D et al.: Prospective, randomized, controlled pilot study of partial liquid ventilation in adult acute respiratory distress syndrome. Am. J. Respir. Crit. Care Med. (2002) 165(6):781-787.
90. KAISERS U, KELLY KP, BUSCH T: Liquid ventilation. Br. J. Anaesth. (2003) 91(1):143-51.
91. DIDLAKE R, KIRCHNER KA, LEWIN J, BOWER HD, MARKAV A: Protection from ischemic renal injury by fructose-1,6-diphosphate infusion in the rat. Circulatory Shock (1985) 16(2):205-212.
92. WANG Y, FOLKESSON HG, JAYR C, WARE LB, MATTHAY MA: Alveolar epithelial fluid transport can be simultaneously upregulated by both KGF and beta-agonist therapy. J. Appl. Physiol. (1999) 87(5):1852-1860.
93. 2-adrenergic agonists stimulate maximal cyclic adenosine monophosphate-dependent airspace fluid clearance and decrease pulmonary edema in experimental acid-induced lung injury. Crit. Care Med. (2004) 32(7):1470-1476.
94. STEINBERG S, DEHRING D, MARTIN D et al.: Amelioration of pulmonary pathophysiology of adult respiratory distress syndrome by sulindac, a cyclo-oxygenase inhibitor. J. Trauma (1987) 67:1103-1110.
95. BERNARD G, WHEELER A, RUSSELL J et al.: The effects of ibuprofen on the physiology and survival of patients with sepsis. N. Engl. J. Med. (1997) 336:912-918.
96. ARONS MM, WHEELER AP, BERNARD GR et al.: Effects of ibuprofen on the physiology and survival of hypothermic sepsis. Crit. Care Med. (1999) 27(4):699-707.
97. HAFNER D, IBRAHIM M, WOLLIN L, GERMANN PG: Cyclooxygenase-inhibition enhances the effects of rSP-C surfactant therapy in a rat lavage model of acute respiratory distress syndrome (ARDS). Exp. Toxicol. Pathol. (2003) 55(1):59-68.
98. GADEK JE, DEMICHELE SJ, KARLSTAD: Effect of enteral feeding with eicosapentaenoic acid, gamma-linolenic acid, and antioxidants in patients with acute respiratory distress syndrome. Crit. Care Med. (1999) 27(8):1409-1420.
99. PACHT ER, DEMICHELE SJ, NELSON JL et al.: Enteral nutrition with eicosapentaenoic acid, gamma-linolenic acid, and antioxidants reduces alveolar inflammatory mediators and protein flux in patients with acute respiratory distress syndrome. Crit. Care Med. (2003) 31(2):491-500.